Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding | Zendy

Sake J. van der Wall | Zendy; Renato D. Lópes | Zendy; James Aisenberg | Zendy; Paul A. Reilly | Zendy; Joanne van Ryn | Zendy; Stephan Glund | Zendy; Amelie Elsaesser | Zendy; Frederikus A. Klok | Zendy; Charles V. Pollack | Zendy; Menno V. Huisman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding

Author(s) -

Sake J. van der Wall,

Renato D. Lópes,

James Aisenberg,

Paul A. Reilly,

Joanne van Ryn,

Stephan Glund,

Amelie Elsaesser,

Frederikus A. Klok,

Charles V. Pollack,

Menno V. Huisman

Publication year - 2019

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.036710

Subject(s) - dabigatran , medicine , idarucizumab , vitamin k antagonist , direct thrombin inhibitor , anesthesia , anticoagulant , gastrointestinal bleeding , atrial fibrillation , prothrombin complex concentrate , bolus (digestion) , warfarin , surgery

Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding, may occur. Therefore, our aim was to provide insights into the efficacy and safety of idarucizumab for urgent dabigatran reversal in patients with major GI bleeding.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research